Clinical Trial Update: Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing AZD4547 versus paclitaxel in advanced gastric cancer and gastroesophageal junction cancer was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• AZD4547
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Gastro-oesophageal Junction Cancer, Gastric Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-07